SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important Deadline in Class Action - KERX
August 12 2016 - 12:14PM
Business Wire
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of Keryx Biopharmaceuticals, Inc. securities
(NASDAQ:KERX) from February 25, 2016 through August 1, 2016, both
dates inclusive (the “Class Period”) of the important October 3,
2016 lead plaintiff deadline in the class action. The lawsuit seeks
to recover damages for Keryx Biopharmaceuticals investors under the
federal securities laws.
To join the Keryx Biopharmaceuticals class action, go to the
firm’s website at http://rosenlegal.com/cases-927.html or call
Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or
email pkim@rosenlegal.com or kchan@rosenlegal.com for more
information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants
issued false and misleading statements to investors and/or failed
to disclose that: (1) Keryx Biopharmaceuticals was experiencing
production-related difficulties in converting API to finished drug
product; (2) the issue was resulting in decreased production yields
of finished drug product; and (3) as a result, defendants’
statements about Keryx Biopharmaceuticals’ business and operations
were false and misleading and/or lacked a reasonable basis. When
the true details entered the market, the lawsuit claims that
investors suffered damages.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
October 3, 2016. A lead plaintiff is a representative party acting
on behalf of other class members in directing the litigation. If
you wish to join the litigation, go to the firm’s website at
http://rosenlegal.com/cases-927.html for more information. You may
also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law
Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com
or kchan@rosenlegal.com. Attorney Advertising. Prior results do not
guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
-------------------------------
Contact Information:
Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.The Rosen
Law Firm, P.A.275 Madison Avenue, 34th FloorNew York, NY 10016Tel:
(212) 686-1060Toll Free: (866) 767-3653Fax: (212)
202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160812005564/en/
Rosen Law Firm866-767-3653Phillip Kim,
Esq.pkim@rosenlegal.comorKevin Chan, Esq.kchan@rosenlegal.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024